Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage’s lead product is approved by the U.S. Food and Drug Administration (FDA) for postpartum depression. Sage is developing a portfolio of novel product candidates targeting critical CNS receptor systems, including SAGE-217, which is in Phase 3 development in major depressive disorder and postpartum depression.
Aug 23, 2019
Copyright Nasdaq. Minimum 15 minutes delayed.
Copyright West LLC. Minimum 15 minutes delayed.
Events & Presentations
Aug 6, 2019 at 8:00 AM EDT
Jul 24, 2019 at 8:00 AM EDT
Jun 25, 2019 at 8:40 AM EDT